Business Wire

NY-URS/UZBEKINVEST

31.7.2024 14:01:33 CEST | Business Wire | Press release

Share
Uzbekinvest Acquires Risk and Capital Modelling Capabilities From Ultimate Risk Solutions Which Helped Them Attain Stable AM Best Rating

Ultimate Risk Solutions (“URS”) is proud to announce its important contribution into assisting Uzbekinvest Export-Import Insurance Company of Uzbekistan (“Uzbekinvest”) in attaining their stable AM Best credit rating. Through the development of advanced risk models of Uzbekinvest’s insurance and reinsurance lines of business, including catastrophe risk, URS has contributed significantly to this achievement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240730430996/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Uzbekinvest acquires risk and capital modelling capabilities from Ultimate Risk Solutions (URS) which helped them attain stable AM Best rating (Graphic: Business Wire)

AM Best, a global credit rating agency specializing in the insurance industry, has revised the outlook for Uzbekinvest from negative to stable. The Financial Strength Rating remains at B (Fair), and the Long-Term Issuer Credit Rating at “bb” (Fair). This positive shift reflects Uzbekinvest’s enhanced risk-adjusted capitalization, in part attributed to the sophisticated risk modelling and probable maximum loss estimation facilitated by URS.

URS’s expertise in risk analysis and modelling has been instrumental in this process, showcasing the company’s commitment to delivering tailored risk solutions that enhance the financial stability and performance of its clients.

“Our company, which is the largest insurance and reinsurance provider in Uzbekistan, has made significant advances in the international markets, and is striving to become a global player closely working with AM Best during the process. Risk and capital modelling capabilities offered by URS technologies allow us to keep an eye on the solvency and stability of our global risk portfolio as it continues to grow,” said Rustam Azimov, General Director of Uzbekinvest.

“We are delighted to have supported Uzbekinvest in their journey towards improved financial strength and stability,” said Alex Bushel, Founder and CEO at Ultimate Risk Solutions. “Our team’s dedication to developing sophisticated and comprehensive risk models underscores our mission to empower our clients with the tools necessary for effective risk management and sustainable growth.”

This collaboration marks a significant milestone for both Uzbekinvest and URS, highlighting the importance of innovative risk management strategies in the insurance sector. As URS continues to pioneer in risk modelling and analysis, it remains committed to helping its clients navigate the complexities of risk with confidence and precision.

About Uzbekinvest:

Uzbekinvest Export-Import Insurance Company JSC is a prominent insurance and reinsurance provider in Uzbekistan and globally. The company is committed to offering reliable and comprehensive insurance and reinsurance solutions to its clients, backed by leading modern technologies and a team of dedicated professionals. This company manages total assets valued at USD 164 million and maintains substantial reserves amounting more than USD 106 million, indicating strong financial stability and capacity to cover potential liabilities. Uzbekinvest boasts a robust global footprint, handling risks from 132 countries. It maintains strong partnerships with major reinsurance companies such as Munich Re, Swiss Re, Allianz, Zurich Insurance Company and collaborates with top-tier broking firms including AON, Willis, Marsh, Guy Carpenter, Howden and others to enhance its market reach and service capabilities.

About Ultimate Risk Solutions:

Ultimate Risk Solutions (URS) is a leading provider of risk modelling and analysis technologies and services, offering advanced solutions for insurance companies and financial institutions globally. With a focus on innovation and precision, URS delivers technologies that help clients enhance their risk management practices and achieve their strategic objectives.

Link to AM Best press release regarding revised Uzbekinvest rating outlook:

https://tinyurl.com/23pcdbck

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240730430996/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release

SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag

Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release

Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a

Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release

Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye